Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice

Jean Holowach Thurston, Richard E. Hauhart, Demoy W. Schulz, Elise F. Naccarato, W. Edwin Dodson, James Edwin Carroll

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Infant mice (2 to 4 days old) received valproate (100 or 200 mg per kilogram body weight) subcutaneously once daily for 5 days, Both dosages decreased plasma β-hydroxybutyrate levels to about one-third of the control value, in the face of normal free fatty acid and glycerol levels. At 200 mg per kilogram of valproate, there were significant decreases in brain weight and brain K content. Both doses produced metabolite changes in brain compatible with a reduced metabolic flux through the glycolytic pathway and the citric acid cycle. Valproate reduced brain aspartate but did not increase brain GABA levels in infant mice. At 200 mg per kilogram of valproate, brain glutamate decreased and taurine levels increased. Two hundred milligrams per kilogram of valproate caused a profound reduction of liver glycogen stores. The apparent decrease in cerebral metabolic rate, reduced glutamate and aspartate, and increased levels of taurine in brain may relate to the anticonvulsant action of valproate. Together with the decreased brain weight and K content, the findings are also compatible with maturational delay. Decreased ketonemia and liver glycogen content may relate to the hepatic toxicity associated with valproate administration in infants and children.

Original languageEnglish (US)
Pages (from-to)1063-1069
Number of pages7
JournalNeurology
Volume31
Issue number9
StatePublished - Jan 1 1981

Fingerprint

Valproic Acid
Liver
Brain
Liver Glycogen
Taurine
Aspartic Acid
Glutamic Acid
Hydroxybutyrates
Weights and Measures
Ketosis
Citric Acid Cycle
Nonesterified Fatty Acids
Anticonvulsants
Glycerol
gamma-Aminobutyric Acid
Body Weight

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Thurston, J. H., Hauhart, R. E., Schulz, D. W., Naccarato, E. F., Dodson, W. E., & Carroll, J. E. (1981). Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice. Neurology, 31(9), 1063-1069.

Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice. / Thurston, Jean Holowach; Hauhart, Richard E.; Schulz, Demoy W.; Naccarato, Elise F.; Dodson, W. Edwin; Carroll, James Edwin.

In: Neurology, Vol. 31, No. 9, 01.01.1981, p. 1063-1069.

Research output: Contribution to journalArticle

Thurston, JH, Hauhart, RE, Schulz, DW, Naccarato, EF, Dodson, WE & Carroll, JE 1981, 'Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice', Neurology, vol. 31, no. 9, pp. 1063-1069.
Thurston JH, Hauhart RE, Schulz DW, Naccarato EF, Dodson WE, Carroll JE. Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice. Neurology. 1981 Jan 1;31(9):1063-1069.
Thurston, Jean Holowach ; Hauhart, Richard E. ; Schulz, Demoy W. ; Naccarato, Elise F. ; Dodson, W. Edwin ; Carroll, James Edwin. / Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice. In: Neurology. 1981 ; Vol. 31, No. 9. pp. 1063-1069.
@article{6381fd554f9246a78e669f22ce6d3add,
title = "Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice",
abstract = "Infant mice (2 to 4 days old) received valproate (100 or 200 mg per kilogram body weight) subcutaneously once daily for 5 days, Both dosages decreased plasma β-hydroxybutyrate levels to about one-third of the control value, in the face of normal free fatty acid and glycerol levels. At 200 mg per kilogram of valproate, there were significant decreases in brain weight and brain K content. Both doses produced metabolite changes in brain compatible with a reduced metabolic flux through the glycolytic pathway and the citric acid cycle. Valproate reduced brain aspartate but did not increase brain GABA levels in infant mice. At 200 mg per kilogram of valproate, brain glutamate decreased and taurine levels increased. Two hundred milligrams per kilogram of valproate caused a profound reduction of liver glycogen stores. The apparent decrease in cerebral metabolic rate, reduced glutamate and aspartate, and increased levels of taurine in brain may relate to the anticonvulsant action of valproate. Together with the decreased brain weight and K content, the findings are also compatible with maturational delay. Decreased ketonemia and liver glycogen content may relate to the hepatic toxicity associated with valproate administration in infants and children.",
author = "Thurston, {Jean Holowach} and Hauhart, {Richard E.} and Schulz, {Demoy W.} and Naccarato, {Elise F.} and Dodson, {W. Edwin} and Carroll, {James Edwin}",
year = "1981",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
pages = "1063--1069",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice

AU - Thurston, Jean Holowach

AU - Hauhart, Richard E.

AU - Schulz, Demoy W.

AU - Naccarato, Elise F.

AU - Dodson, W. Edwin

AU - Carroll, James Edwin

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Infant mice (2 to 4 days old) received valproate (100 or 200 mg per kilogram body weight) subcutaneously once daily for 5 days, Both dosages decreased plasma β-hydroxybutyrate levels to about one-third of the control value, in the face of normal free fatty acid and glycerol levels. At 200 mg per kilogram of valproate, there were significant decreases in brain weight and brain K content. Both doses produced metabolite changes in brain compatible with a reduced metabolic flux through the glycolytic pathway and the citric acid cycle. Valproate reduced brain aspartate but did not increase brain GABA levels in infant mice. At 200 mg per kilogram of valproate, brain glutamate decreased and taurine levels increased. Two hundred milligrams per kilogram of valproate caused a profound reduction of liver glycogen stores. The apparent decrease in cerebral metabolic rate, reduced glutamate and aspartate, and increased levels of taurine in brain may relate to the anticonvulsant action of valproate. Together with the decreased brain weight and K content, the findings are also compatible with maturational delay. Decreased ketonemia and liver glycogen content may relate to the hepatic toxicity associated with valproate administration in infants and children.

AB - Infant mice (2 to 4 days old) received valproate (100 or 200 mg per kilogram body weight) subcutaneously once daily for 5 days, Both dosages decreased plasma β-hydroxybutyrate levels to about one-third of the control value, in the face of normal free fatty acid and glycerol levels. At 200 mg per kilogram of valproate, there were significant decreases in brain weight and brain K content. Both doses produced metabolite changes in brain compatible with a reduced metabolic flux through the glycolytic pathway and the citric acid cycle. Valproate reduced brain aspartate but did not increase brain GABA levels in infant mice. At 200 mg per kilogram of valproate, brain glutamate decreased and taurine levels increased. Two hundred milligrams per kilogram of valproate caused a profound reduction of liver glycogen stores. The apparent decrease in cerebral metabolic rate, reduced glutamate and aspartate, and increased levels of taurine in brain may relate to the anticonvulsant action of valproate. Together with the decreased brain weight and K content, the findings are also compatible with maturational delay. Decreased ketonemia and liver glycogen content may relate to the hepatic toxicity associated with valproate administration in infants and children.

UR - http://www.scopus.com/inward/record.url?scp=0019446390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019446390&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1063

EP - 1069

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -